Literature DB >> 9531582

Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications.

L Escribano1, A Orfao, B Díaz-Agustin, J Villarrubia, C Cerveró, A López, M A Marcos, C Bellas, S Fernández-Cañadas, M Cuevas, A Sánchez, J L Velasco, J L Navarro, J F Miguel.   

Abstract

The aim of the present study was to explore the diagnostic value of the immunophenotypic analysis of bone marrow mast cells (BMMC) in indolent systemic mast cell disease (SMCD) patients. For that purpose, a total of 10 SMCD patients and 19 healthy controls were analyzed. Our results show that BMMC from SMCD are different from normal BMMC with regard to both their light scatter and immunophenotypic characteristics. Accordingly, forward light scatter (FSC), side (90 degrees) light scatter (SSC), and baseline autofluorescence levels were higher in BMMC from indolent SMCD patients than they were in control subjects. From the immunophenotypic point of view, the most striking findings were the constant expression of CD2 (P = .0001), CD25 (P = .0001), and CD35 (P = .06) molecules by BMMC from SMCD patients, markers that were absent from all normal controls. In contrast, CD71, absent in BMMC from indolent SMCD, was positive in BMMC from normal subjects. Although, slight differences between BMMC from SMCD patients and normal controls were found in several other markers, they did not reach statistical significance. In conclusion, our results show that simultaneous assessment of FSC/SSC and reactivity for the CD117, CD2, CD25, CD33, and CD35 forms the basis for the immunophenotypic characterization of BMMC from SMCD in adults and should be integrated with clinical and morphologic studies for the diagnosis of the disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531582

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Extensive characterization of the immunophenotype and pattern of cytokine production by distinct subpopulations of normal human peripheral blood MHC II+/lineage- cells.

Authors:  J Almeida; C Bueno; M C Alguero; M L Sanchez; M C Cañizo; M E Fernandez; J M Vaquero; F J Laso; L Escribano; J F San Miguel; A Orfao
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 2.  Mastocytosis and disorders of mast cell proliferation.

Authors:  Joanne K Simpson; Dean D Metcalfe
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

3.  Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm.

Authors:  T Gülen; B Sander; G Nilsson; J Palmblad; K Sotlar; H-P Horny; H Hägglund
Journal:  Med Oncol       Date:  2012-06-03       Impact factor: 3.064

Review 4.  Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment.

Authors:  Cem Akin; Peter Valent; Luis Escribano
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

5.  Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI.

Authors:  Tanya M Laidlaw; John W Steinke; Adrienne M Tiñana; Chunli Feng; Wei Xing; Bing K Lam; Sailaja Paruchuri; Joshua A Boyce; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2011-02-01       Impact factor: 10.793

6.  Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis.

Authors:  Cem Akin; Linda M Scott; Can N Kocabas; Nataliya Kushnir-Sukhov; Erica Brittain; Pierre Noel; Dean D Metcalfe
Journal:  Blood       Date:  2007-07-16       Impact factor: 22.113

Review 7.  Mast cells and mastocytosis.

Authors:  Dean D Metcalfe
Journal:  Blood       Date:  2008-08-15       Impact factor: 22.113

8.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

9.  High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.

Authors:  Robert Fritsche-Polanz; Marika Fritz; Andrea Huber; Karl Sotlar; Wolfgang R Sperr; Christine Mannhalter; Manuela Födinger; Peter Valent
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

10.  CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen.

Authors:  Shiteng Duan; Cynthia J Koziol-White; William F Jester; Scott A Smith; Corwin M Nycholat; Matthew S Macauley; Reynold A Panettieri; James C Paulson
Journal:  J Clin Invest       Date:  2019-02-18       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.